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GlutathioneAbstract Propionic acid, a metabolite produced by intestinal bacteria, has been implicated in aut-
ism. N-Acetylcysteine is a well-known antioxidant. The present study investigated the protective
effects of N-Acetylcysteine on propionic acid-induced neurotoxicity in rat pups. Male Western
albino rats were divided into four groups. The ﬁrst group served as the normal control group,
the second was treated with propionic acid (PA group), the third group received propionic acid fol-
lowed by N-Acetylcysteine (PANA group), and the fourth group received N-Acetylcysteine fol-
lowed by propionic acid (NAPA group). In the PA group, there was a signiﬁcant increase in
lactate dehydrogenase activity, decrease in glutathione levels, and decrease in sodium levels
(P< 0.05, all comparisons). Calcium and potassium levels did not signiﬁcantly change. Addition-
ally, urea and lipid peroxide levels were signiﬁcantly elevated in propionic acid-intoxicated rats and
signiﬁcantly rescued in the N-Acetylcysteine-treated groups (P< 0.05, all comparisons). These
results indicate that N-Acetylcysteine can both protect against and treat propionic acid intoxica-
tion.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Propionic acid is a natural body metabolite that is utilised by
most organs and tissues. It is produced as a result of fermenta-
tion of undigested carbohydrates by intestinal bacteria (Jan
et al., 2002; Al-Lahham et al., 2010; Nyhan et al., 1999;
Thompson et al., 1990; Zarate et al., 2004). Propionates alsoexist naturally in various foods, especially dairy products. In
addition, studies have reported that several bacteria, such as
clostridia, produce propionic acid during their natural metab-
olism (Finegold et al., 2010). Consumption of excessive propi-
onate in children results in irritability, inattention, and
restlessness associated with sleep disorders (Dengate and
Ruben, 2002). Propionic acid crosses the blood–brain barrier
and can cause mild, reversible intracellular acidiﬁcation, which
can affect the release of neurotransmitters including glutamate,
dopamine, and serotonin (Gupta and Deshpande, 2008; Song
et al., 2004). Propionic acid can increase N-methyl-D-aspartate
(NMDA) receptor sensitivity, promote intracellular calcium
release, elevate nitric oxide levels, and inhibit Na+/K+ATP-
ase, all of which can inﬂuence synaptic transmission and/or
neuronal activity (Bronstein et al., 1993; Wajner et al., 2004;
N-Acetylcysteine reduces the neurotoxic effects of propionic acid in rat pups 255DeMattos-Dutra et al., 2000). Mitochondrial fatty acid metab-
olism may be affected by propionic acid because of its interac-
tion with propionyl coenzyme A and sequestration of carnitine
(Wajner et al., 2004; Brass et al., 1986). This impaired fatty
acid metabolism may be related to autism, which may be a
mitochondrial disorder.
N-Acetylcysteine, a derivative of the amino acid L-Cysteine,
is currently used as an antioxidant, nutritional supplement,
and pharmaceutical drug. It is an excellent source of sulphyd-
ryl groups and can be converted into metabolites that can ele-
vate glutathione synthesis in the body. N-Acetylcysteine is
currently used as a mucolytic agent for respiratory diseases.
It is also used to treat paracetamol overdoses (Tsai et al.,
2005), in which case it acts by promoting detoxiﬁcation by
increasing free radical scavenger activity, thus maintaining
normal glutathione levels in hepatocytes. N-Acetylcysteine is
a precursor for glutathione, which acts as a free radical scaven-
ger in neurons (Cooper and Kristal, 1997) and improves neu-
ronal survival (Ratan et al., 1994). These functions are
performed by preserving mitochondrial function and main-
taining the mitochondrial oxidative metabolism by protecting
the cytochrome oxidase complex I from NO-mediated damage
(Moncada, 2000). N-Acetylcysteine can also act as a heavy me-
tal chelating agent to clear the body of some toxic metals.
Additionally, N-Acetylcysteine raises glutathione levels when
taken as a supplement by immunocompromised patients.Table 1 The one-way ANOVA test between the control, PPA a
Glutathione (ug/ml), Calcium (mmol/L), Potassium (mmol/l), Urea (m
as multiple comparisons.
Parameters Groups Min.
LD enzyme (U/L) Control 102.18
PPA 112.06
N-acetyl protective 102.18
N-acetyl therapeutic 29.66
Sodium (mmol/l) Control 48.99
PPA 22.00
N-acetyl protective 18.20
N-acetyl therapeutic 9.70
Glutathione (ug/ml) Control 34.48
PPA 23.27
N-acetyl protective 32.32
N-acetyl therapeutic 20.68
Calcium (mmol/L) Control 1.75
PPA 1.84
N-acetyl protective 2.15
N-acetyl therapeutic 2.07
Potassium (mmol/l) Control 4.70
PPA 4.46
N-acetyl protective 6.09
N-acetyl therapeutic 5.18
Urea (mmol/L) Control 4.97
PPA 7.08
N-acetyl protective 6.73
N-acetyl therapeutic 5.96
Lipid peroxides (nmole/ml) Control 1.02
PPA 2.33
N-acetyl protective 1.28
N-acetyl therapeutic 1.50
Signiﬁcant levels between the three groups are illustrated as superscript lThe purpose of this study was to examine the toxic effect of
propionic acid on rat pups and evaluate the potential neuro-
protective effects of N-Acetylcysteine on propionic acid-in-
duced neurotoxicity.2. Materials and methods
2.1. Animals
Twenty Male Western albino rats (approximately 4 weeks old,
weighing 45–60 g) were used in this study. They were sepa-
rately housed at a controlled temperature of 21 ± 1 C with
ad libitum access to food and water.
2.2. Experimental design
The experimental design and treatment schedule was as
follows:
Group 1: Control rats that did not receive any treatment
(Normal healthy control; control group).
Group 2: Rats treated with a neurotoxic dose of propionic
acid (purchased from Sigma) (250 mg/kg body weight over
three days) to induce autism (PA group).nd OMEGA groups in LD enzyme (U/L), Sodium (mmol/l),
mol/L) and Lipid peroxide (nmole/ml) groups and Dunnett test
Max. Percent change Mean ± S.D. P value
253.79 100.00 160.89 ± 50.76 0.001
372.45 160.962 258.96 ± 85.94 a
288.41 108.920 175.24 ± 84.71
125.25 40.563 65.26 ± 36.70 a
95.00 100.00 66.94 ± 17.37 0.001
62.99 61.01 40.84 ± 13.80 a
58.80 54.70 36.62 ± 15.00 a
26.60 24.90 16.67 ± 7.75 a
37.06 100.00 35.57 ± 0.96 0.001
31.03 78.25 27.83 ± 3.20 a
36.20 96.10 34.18 ± 1.52
28.01 68.46 24.35 ± 2.54 a
3.45 100.00 2.42 ± 0.54 0.169
2.38 84.37 2.04 ± 0.17
2.62 96.87 2.34 ± 0.19
2.39 91.82 2.22 ± 0.13
8.32 100.00 6.40 ± 1.16 0.166
6.87 88.89 5.69 ± 0.97
7.49 104.12 6.67 ± 0.59
7.92 107.48 6.88 ± 1.02
8.59 100.00 6.49 ± 1.23 0.012
10.06 128.54 8.34 ± 1.20 a
8.24 113.66 7.38 ± 0.58
7.72 107.49 6.98 ± 0.64
1.70 100.00 1.40 ± 0.24 0.001
6.54 295.30 4.13 ± 1.37 a
2.09 115.86 1.62 ± 0.37
1.81 118.22 1.65 ± 0.10
etters when P< 0.05.
256 A.M. Al-DbassGroup 3: Rats treated with N-Acetylcysteine (purchased
from Sigma) (50 mg/kg body weight over a period of one
week), followed by propionic acid intoxication as described
above (NAPA group).
Group 4: Rats treated with a toxic dose of propionic acid
followed by N-Acetylcysteine (PANA group).
2.3. Ethics approval and consent
The Ethics committee of the College of Science Research Cen-
tre of King Saud University, Riyadh, Saudi Arabia approved
this study. The approval number is 8/25/220358.
2.4. Blood collection
At the end of the experimental period, the rats were sacriﬁced
using ether anaesthesia. Blood samples were collected from the
inferior vena cava of each rat. The serum was separated from
the blood cells and stored at 80 C until analysis.Figure 1 Percentage change of control, PPA, N-acetyl protective and N
Glutathione (ug/ml), Calcium (mmol/L), Potassium (mmol/l), Urea (mm
ROC Curve
1 - Specificity
1.00.75.50.250.00
Se
ns
iti
vi
ty
1.00
.75
.50
.25
0.00
Source of the Curve
Reference Line
Lipid Peroxides (nmo
le/ml)
Urea (mmol/L)
LD enzyme (U/L)
Figure 2 ROC Curve of LD enzyme (U/L), Sodium (mmol/l), Glu
(mmol/L) and Lipid peroxides (nmole/ml) in the PPA group.2.5. Biochemical analysis
2.5.1. Measurement of lactate dehydrogenase (LD)
The activity of LD5 was measured with the pyruvate to lactate
kinetic method and the two-point colorimetric method for lac-
tate dehydrogenase (LD). An increase in the absorbance at
340 nm indicated NADH formation, which was directly pro-
portional to serum LD-L activity. The procedure was based
on the modiﬁcations of the Amador and Wacker method
(Amador et al., 1963; Snodgrass et al., 1959).
2.5.2. Determination of sodium levels
Sodium levels were assayed by enzymatic determination of so-
dium, i.e., measurement of sodium-dependent galactosidase
activity using ONPG as a substrate (Tiez, 1986).
2.5.3. Determination of glutathione levels
Glutathione levels were measured by the development of a rel-
atively stable yellow colour (read at 412 nm) upon addition of
5, 5-dithiobis-2-nitrobenzoic acid (Beutler et al., 1963).-acetyl therapeutic groups in LD enzyme (U/L), Sodium (mmol/l),
ol/L) and Lipid peroxide (nmole/ml) groups compared to control.
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Figure 3 ROC Curve of LD enzyme (U/L), Sodium (mmol/l), Glutathione (ug/ml), Calcium (mmol/L), Potassium (mmol/l), Urea
(mmol/L) and Lipid peroxides (nmole/ml) in the N-acetyl protective group.
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Calcium levels were measured using a procedure involving a
chromogenic complex that forms upon reaction of o-cresolph-
thalein complexone (o-CPC) with calcium. The chromogenic
complex absorbs light and was therefore measured photomet-
rically between 570 nm and 580 nm (Faulker and Meites,
1982).
2.5.5. Determination of potassium levels
Potassium levels were measured in a protein-free alkaline med-
ium by reaction with sodium tetraphenyl boron, which
produced a colloidal suspension. The turbidity of such aTable 2 ROC analysis parameters showing area under the curve, cu
in the four studied groups.
Group parameter Area under
PPA LD enzyme (U/L)
Sodium (mmol/l)
Glutathione (ug/m
Calcium (mmol/L)
Potassium (mmol/l
Urea (mmol/L)
Lipid peroxides
(nmole/ml)
N-acetyl protective LD enzyme (U/L)
Sodium (mmol/l)
Glutathione (ug/m
Calcium (mmol/L)
Potassium (mmol/l
Urea (mmol/L)
Lipid peroxides
(nmole/ml)
N-acetyl therapeutic LD enzyme (U/L)
Sodium (mmol/l)
Glutathione (ug/m
Calcium (mmol/L)
Potassium (mmol/l
Urea (mmol/L)
Lipid peroxides
(nmole/ml)suspension is proportional to the potassium concentrations
in the range of 2–7 mmol/L (Terri and Sesin, 1958).
2.5.6. Determination of urea levels
Urea levels were measured using the enzymatic, colorimetric,
endpoint-Berthelot method (Kits from Crescent Diagnostics
Co., Saudi Arabia), in which the conversion of urea to ammo-
nia was catalysed by urease.
2.5.7. Determination of lipid peroxide levels
Endogenous lipid peroxidation was evaluated by measuring
the malondialdehyde concentration at 532 nm and calculatingtoff values, sensitivity and speciﬁcity of the measured parameters
The
curve
Cutoﬀ Value
(%)
Sensitivity (%)
Speciﬁcity (%)
0.821 201.880 85.7 87.5
0.929 47.595 85.7 100.0
l) 1.000 32.755 100.0 100.0
0.750 2.394 100.0 62.5
) 0.661 6.510 85.7 50.0
0.893 7.035 100.0 75.0
1.000 2.016 100.0 100.0
0.479 262.031 33.3 100.0
0.917 47.595 83.3 100.0
l) 0.781 34.265 66.7 100.0
0.521 2.346 66.7 62.5
) 0.563 5.866 100.0 37.5
0.750 6.602 100.0 62.5
0.667 1.276 100.0 37.5
0.958 96.408 83.3 100.0
1.000 37.795 100.0 100.0
l) 1.000 31.245 100.0 100.0
0.667 2.396 100.0 62.5
) 0.625 6.846 66.7 75.0
0.677 6.506 83.3 62.5
0.802 1.478 100.0 62.5
258 A.M. Al-Dbassthe concentration using an extinction coefﬁcient value (€) of
156 * 105 M1 cm1 (Buege and Aust, 1978).
2.6. Statistical analysis
The one-way analysis of variance (ANOVA) was used for sta-
tistical analysis. The values were expressed as means ± stan-
dard deviation. A P value of <0.05 was considered
statistically signiﬁcant. The Receiver Operating Characteristic
(ROC) curve is a fundamental tool for evaluating biomarkers.
On the ROC curves, the true positive rate was plotted against
the false positive rate (100-Speciﬁcity) for various cut-off
values.
3. Results
Table 1 and Fig. 1 present the neurotoxic effects of propionic
acid along with the protective and therapeutic effects of N-
Acetylcysteine. Propionic acid induced signiﬁcant increases in
serum LD activity and oxidative stress through the induction
of glutathione depletion and a signiﬁcant increase in lipid per-
oxidation (P< 0.05). Propionic acid did not affect calcium or
potassium levels but did induce sodium depletion. Urea levels
were dramatically elevated in the serum of propionic acid-trea-
ted rats. Table 1 shows the protective effect of N-Acetylcyste-ROC Curve
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Figure 4 ROC Curve of LD enzyme (U/L), Sodium (mmol/l), Glu
(mmol/L) and Lipid peroxides (nmole/ml) in the N-acetyl therapeuticine on propionic acid neurotoxicity. N-Acetylcysteine-pre-
treated rats had much lower LD activity and lipid peroxidation
and higher levels of glutathione. N-Acetylcysteine treatment
did not affect sodium levels.
Table 2 and Figs. 2–4 display ROC curves for the parame-
ters measured, including the area under the curve, cut-off, and
speciﬁcity and sensitivity values.
4. Discussion
Propionic acid toxicity is an organic acidemia (Xu et al., 2012)
that is often present during the neonatal period along with
lethargy, poor feeding, and vomiting. Progression may lead
to coma if not recognised and appropriately treated. Table 1
and Fig. 1 show a dramatic increase in LD activity in the plas-
ma of propionic acid-treated rats compared to the control
group. The increase in LD in the serum could be due to the
leakage of enzyme from the brain into the plasma, which
may indicate cellular and membrane damage. El-Ansary
et al.’s (2011) study supports this observation. They found a
remarkable decrease in LD activity in the brain homogenates
of propionic acid-treated rats compared to untreated controls
(El-Ansary et al., 2011). The outcomes of our study indicate
that N-Acetylcysteine is effective against propionic acid-in-
duced neurotoxicity (Table 1). N-Acetylcysteine has both pro-ROC Curve
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els of LD activity in the serum. Hsu et al. (2006) showed that
pre- versus post-treatment with N-Acetylcysteine decreases
plasma LD as a marker of organ injury induced during sepsis.
Additionally, the protective effects shown in our study agree
with Abd El-Fattah and El-Sheikh (2012), who reported that
N-Acetylcysteine partially corrects propionic acid-induced
changes in enzyme activities and protects the kidney from
tubular damage.
Increased oxidative damage due to neuroinﬂammation,
mitochondrial dysfunction, and impaired GSH metabolism
may be related to the development of autism (James et al.,
2004; Al-Gadani et al., 2009). Oxidative stress has been impli-
cated in synaptic plasticity. MacFabe et al. (2007) and El-An-
sary et al. (2012) hypothesised that similar processes could
arise in animals given an oral or intraventricular neurotoxic
dose of propionic acid. We have found that propionic acid
treatment induces a substantial increase in lipid oxidation,
indicating increased oxidative stress. We found that N-Acetyl-
cysteine exerted a protective effect on GSH depletion induced
by propionic acid and a smaller effect when given after propi-
onic. Increased lipid peroxide levels serve as a marker for the
neurotoxic effects of propionic acid. The antioxidant effect
of N-Acetylcysteine was conﬁrmed by its ability to decrease
the concentration of lipid peroxides. Hence, N-Acetylcysteine
exerts both protective and therapeutic effects. The effectiveness
of N-Acetylcysteine is due to increases in cysteine levels that
increase the available pool of glutathione, compared to other
antioxidants examined in autism. Previous studies support this
suggested antioxidant effect. For example, Gibson et al. (2009)
concluded that N-Acetylcysteine is a weak antioxidant that re-
quires prior conversion into GSH to impart antioxidant and
antithrombotic beneﬁts at therapeutic levels. Additionally,
N-Acetylcysteine acted as an antiplatelet agent only when
the intra-platelet activity that converts it into GSH is func-
tional (Gibson et al., 2011). The failure of N-Acetylcysteine
to exert a therapeutic antioxidant effect in the present study
may suggest that propionic acid irreversibly impaired the glu-
tathione synthesis pathway.
The effectiveness of the low dose of N-Acetylcysteine
(50 mg/kg/day) used in the present study concurs with a previ-
ous animal study by Sprong et al. (1998). In their study, high-
dose N-Acetylcysteine treatment (550 and 950 mg/kg in 48 h)
decreased lung glutathione (75 mg/kg/day) and resulted in a
signiﬁcantly lower survival rate compared to low-dose N-Ace-
tylcysteine (Sprong et al., 1998).
Our results indicate that hyponatraemia could be one of the
neurotoxic effects of propionic acid (Table 1). Although plas-
ma calcium and potassium levels were not signiﬁcantly altered
by propionic acid, plasma sodium levels were dramatically de-
creased. We found that N-Acetylcysteine was not effective at
ameliorating propionic acid-induced hyponatraemia (Table 1).
This observation indicates that N-Acetylcysteine is likely to
work through the proposed anti-oxidative mechanism. Addi-
tionally, the weak therapeutic effect of N-Acetylcysteine in
the present study concurs with a study by El-Ansary et al.
(2012) on the persistent neurotoxic effects of propionic acid
and the induction of biochemical autistic features in rats.
Intraperitoneal administration was selected to test the role
of the gut-brain axis in the neurotoxicity of propionic acid
and the possibility of treating autistic patients through oral
administration of N-Acetylcysteine.5. Conclusion
The outcomes of this study indicate that N-Acetylcysteine
could be used to both protect against and treat propionic acid
intoxication.Acknowledgement
This research project was supported by a grant from the re-
search centre of the Centre for Female Scientiﬁc and Medical
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